Deciphera Pharmaceuticals

Deciphera Pharmaceuticals Operating Expenses

Delisted·Jun 10, 2024

The Total Operating Expenses of Deciphera Pharmaceuticals (DCPH) as of Nov 21, 2026 is 363.63 M USD. In the previous year, Total Operating Expenses was 307.99 M USD — a change of 18.07% (higher).

Operating Expenses

363.63 MUSD

YoY

18.07%

Last updated:

Total Operating Expenses of Deciphera Pharmaceuticals is 2023 363.63 M USD. Total Operating Expenses of Deciphera Pharmaceuticals was 2022 307.99 M USD. It decreases by 18.07% higher compared to the previous year.

The Deciphera Pharmaceuticals Operating Expenses history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Operating Expenses
Date
Operating Expenses
Jan 1, 2016
25.84 M USD
Jan 1, 2017
50.94 M USD
Jan 1, 2018
104.10 M USD
Jan 1, 2019
225.73 M USD
Jan 1, 2020
313.05 M USD
Jan 1, 2021
393.29 M USD
Jan 1, 2022
307.99 M USD
Jan 1, 2023
363.63 M USD
The Deciphera Pharmaceuticals Operating Expenses history
YEAROperating ExpensesYoY
363.63 MUSD+18.07%
307.99 MUSD-21.69%
393.29 MUSD+25.63%
313.05 MUSD+38.69%
225.73 MUSD+116.84%
104.10 MUSD+104.38%
50.94 MUSD+97.13%
25.84 MUSD+46.72%
17.61 MUSD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Deciphera Pharmaceuticals Stock analysis

What does Deciphera Pharmaceuticals do? Deciphera Pharmaceuticals Inc is a US biopharmaceutical company specializing in the research, development, and marketing of innovative therapeutic solutions for cancer patients. The company was founded in 2003 and is headquartered in Waltham, Massachusetts. Deciphera follows a diversified business model based on multiple pillars. On one hand, the company conducts its own research and development activities to develop new therapy approaches for cancer patients. Deciphera focuses on the research of kinase inhibitors, which offer promising approaches in cancer therapy. On the other hand, the company pursues a licensing strategy by acquiring and further developing already developed active ingredients for cancer therapies in order to make them available to patients. For this purpose, the company collaborates with various partner companies and leading academics and experts in the field of cancer therapy. Deciphera is also engaged in international collaboration through partnerships with local partners in Asia for the research of new cancer therapy approaches. The company invests significant efforts in research and development to constantly adapt its products to the latest scientific advances. Deciphera aims to develop effective and safe therapies for cancer patients that improve their quality of life and increase their chances of survival. The company relies on the research of kinase inhibitors that specifically target certain signaling pathways in cancer cells and thereby inhibit the growth of tumor cells. The company already has a number of products in clinical trials and approval processes that show promising results and are expected to be on the market soon. One promising drug is Ripretinib, dedicated to the cancer type GIST. The goal is to offer a range of cancer medications that have significant treatment success and offer customers high chances of success. Overall, Deciphera Pharmaceuticals is a dynamic and research-oriented company that utilizes the most innovative technologies to give hope to cancer patients and improve the treatment of cancer diseases. With its broad portfolio of active ingredients and therapy approaches, its international presence, and its dedicated research and development, Deciphera Pharmaceuticals Inc. is at the forefront when it comes to innovative cancer treatment therapies. Deciphera Pharmaceuticals is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Deciphera Pharmaceuticals stock

Total Operating Expenses of Deciphera Pharmaceuticals is 363.63 M USD in 2023.

Total Operating Expenses of Deciphera Pharmaceuticals changed from 307.99 M USD to 363.63 M USD, representing a 18.07% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Total Operating Expenses Deciphera Pharmaceuticals since 2006 – with annual values, charts, and detailed analysis.

Operating expenses are the costs incurred in the normal course of business operations, including COGS, SG&A, R&D, and depreciation.

Total Operating Expenses's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Total Operating Expenses's Deciphera Pharmaceuticals historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Income Statement — Deciphera Pharmaceuticals

All Key Metrics — Deciphera Pharmaceuticals